The Cigna Group
Moat Score — The Cigna Group
Total Moat Score
17 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Cigna's brand carries some trust in employer and health-plan markets, but the deeper advantage is regulatory licensure and accumulated claims/underwriting data rather than classic brand or patent protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 4 / 5 | Evernorth's massive prescription claims volume gives Cigna outsized leverage to negotiate drug rebates and administrative costs that smaller PBMs and standalone insurers cannot match. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Pricing is constrained by sophisticated employer/health-plan buyers, competitive bidding, and intense political and regulatory scrutiny of PBM and insurance pricing practices. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | A larger PBM network offers modestly better pharmacy access and data leverage, but this is a weak, indirect effect compared to true network-effect businesses. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Employers and health plans face substantial disruption, data migration, and member-experience risk when switching insurers or PBMs, and contracts typically run multi-year terms. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 4 / 5 | The integrated payer-PBM model is effectively an oligopoly of a handful of players (UnitedHealth/Optum, CVS/Caremark, Cigna/Evernorth) with scale requirements that make new entry very difficult. |